Page 1231 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1217

life cycle of, 870, 874f action of, 127, 128f fibric acid derivatives and bile-acid
retroviral agents in, 870–884. See also antiemetic properties of, 1106 binding resins, 639
Retroviral agents Hyoscyamine. See also Atropine; Muscarinic HMG CoA reductase inhibitors and
with tuberculosis, antimycobacterial receptor blockers bile-acid binding resins, 639
drugs for, 842, 852 description of, 125, 135t niacin and bile-acid binding resins,
Human menopausal gonadotropin (hMG), irritable bowel syndrome treated with, 639
673–674. See also Gonadotropins 1101 niacin and reductase inhibitors, 639
Human papillomavirus (HPV) vaccine, Hyperalgesia, opioid-induced, 559 reductase inhibitors and ezetimibe,
1176t Hypercalcemia 639
Human placenta derivatives, 1133t description of, 782–783 reductase inhibitors and fenofibrate,
Humoral immunity, 979 diuretics for, 272 639
Huntington’s disease, 504f, 504–505, 508t Hypercalciuria, idiopathic, 788 resins, ezetimibe, niacin, and reductase
Hydatid disease. See also Anthelmintic drugs Hyperchloremic metabolic acidosis inhibitors, 639
albendazole for, 939t, 940 carbonic anhydrase inhibitors as cause use of, 638
praziquantel for, 944–945 of, 261 fibric acid derivatives, 634–635, 635f
Hydralazine potassium-sparing diuretics as cause of, HMG-CoA reductase inhibitors, com-
heart failure treated with, 222, 225t 267 petitive, 632–634, 633f, 639t
hypertension treated with, 179t, Hypercholesterolemias, primary intestinal sterol absorption inhibitors,
184–185, 191t ABCG5 and ABCG8 mutations, 631 637, 640t
Hydrocarbons autosomal recessive hypercholesterolemia, microsomal triglyceride transfer protein
aromatic, 1009–1010 631 inhibitor, 638
halogenated aliphatic, 1009 cholesterol 7α-hydroxylase, 631 niacin, 636, 640t
inhalants, ionotropic receptors in, 585 cholesteryl ester storage disease, 629t, Hyperlipoproteinemias, 627–631, 629t
Hydrochlorothiazide. See also Diuretics 631 definition of, 626
description of, 191t, 224t, 264f, dietary management for, 632 dietary management, 632
264–265, 273t familial combined hyperlipoproteinemia, pathophysiology of, 627–631, 628f
hypercalciuria treated with, 788 629t, 631 secondary, 631
Hydrocodone, 555t, 568, 572t. See also familial hypercholesterolemia, 629t, 630, Hypernatremia, 267–268
Opioid agonists 631f Hyperosmolar hyperglycemic syndrome
Hydrocortisone familial ligand-defective apolipoprotein (HHS), 767–768
case study of, 719 B-100, 629t, 630 Hyperparathyroidism, primary, 784
natural, 704–709. See also Glucocorti- HDL deficiency, 631 Hyperphosphatemia, 784
coids, naturally occurring Lp(a) hyperlipoproteinemia, 629t, 631 Hyperprolactinemia
preparations available, 718t PCSK9, 631 antipsychotics as cause of, 522
synthetic, 709t, 710 Hyperglycemia dopamine agonists for, 679, 680f
topical, 1079–1081, 1080t, 1081t antipsychotics as cause of, 522 ergot alkaloids for, 295
Hydroeicosatetraenoic acid. See HETE thiazide diuretics as cause of, 265 Hyperreactive, 38
Hydrogen cyanide, 1041t, 1044, 1044t Hyperhidrosis, 133 Hypersecretory conditions, proton-pump
Hydrogen peroxide, 900–901 Hypericum perforatum, 1139–1140 inhibitors for, 1094
Hydrolyses, 61t Hyperimmune immunoglobulins, 991 Hypersensitivity reactions, 38, 981–983,
Hydromorphone, 555t, 567, 572t. See also Hyperkalemia, 231b 983f
Opioid agonists loop diuretics for, 263 drug-induced, 83t, 83–85, 84f
Hydrophobic bonds, 3–4 mannitol as cause of, 267–268 type I, 982, 983f, 998–999
Hydroquinone, 1076 neuromuscular blockers as cause of, 483 type II, 982–983, 999
Hydroxocobalamin, 596, 598, 606t potassium-sparing diuretics as cause of, type III, 952f, 983, 999–1000
Hydroxychloroquine 266–267 type IV (delayed-type), 983, 984f
immunosuppressive uses of, 989 Hyperlipidemia, 627–632. See also Hypertension
rheumatoid arthritis treated with, 650 Hyperlipoproteinemias agents for, 173–193
5-Hydroxyindoleacetic acid, 286 antipsychotics as cause of, 522 alcohol consumption and, 401
Hydroxyprogesterone, 729f coronary artery disease with, 194, 211 b-receptor antagonists for, 167
Hydroxyprogesterone caproate, 728t. See thiazide diuretics as cause of, 265 carbonic anhydrase inhibitors for,
also Progestins Hyperlipidemia drugs, 632–638, 640t 259–260
5-Hydroxytryptamine, 285–292 AMP kinase activation, 638 case study on, 173, 193
Hydroxyurea, 592b apo B-100 synthesis antisense inhibition, classification of, 173–174, 174t
Hydroxyzine, 283t, 383 638 coronary artery disease and, anesthesia
Hymenolepis nana, 945 bile acid-binding resins, 636–637, 640t with, 440
Hyoscine, 125. See also Muscarinic receptor CETP inhibition, 638 diagnosis of, 173–174
blockers combinations diuretics for, 271